National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, 9, Ireland,
Cytotechnology. 2007 Apr;53(1-3):65-73. doi: 10.1007/s10616-007-9050-y. Epub 2007 Feb 28.
Considerable increases in productivity have been achieved in biopharmaceutical production processes over the last two decades. Much of this has been a result of improvements in media formulation and process development. Though advances have been made in cell line development, there remains considerable opportunity for improvement in this area. The wealth of transcriptional and proteomic data being generated currently hold the promise of specific molecular interventions to improve the performance of production cell lines in the bioreactor. Achieving this-particularly for multi-gene modification-will require specific, targeted and controlled genetic manipulation of these cells. This review considers some of the current and potential future techniques that might be employed to realise this goal.
在过去的二十年中，生物制药生产工艺的生产力有了显著提高。这在很大程度上是由于培养基配方和工艺开发的改进。尽管在细胞系开发方面取得了进展，但在这一领域仍有很大的改进空间。目前产生的大量转录组和蛋白质组数据有望通过特定的分子干预来提高生物反应器中生产细胞系的性能。实现这一目标——特别是对于多基因修饰——需要对这些细胞进行特定的、有针对性的和可控的遗传操作。本文综述了一些当前和潜在的未来技术，这些技术可能被用于实现这一目标。
